Inhibitors against glycosidases as medicines.
Glycosidases mediate the digestion of oligosaccharides in the small intestine as well as the processing of cell surface oligosaccharides, which play important roles in cell to cell recognition during infections, metastasis, and immune responses. Thus, agents that control the activities of glycosidases could have therapeutic effects against many carbohydrate-related diseases. In fact, many fruitful efforts have been made to design and synthesize glycosidase inhibitors as clinically practical medicines. This review summarizes the current stage of development of such inhibitors to treat diabetes, influenza, virus infection of HIV, tumor metastasis, and glycosyl sphingo lipid (GSL) storage diseases.
Kajimoto
Tetsuya
T
Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan. kajimoto@mb.kyoto-phu.ac.jp
Node
Manabu
M
D000998:Antiviral Agents / Q000737:chemistry / Q000627:therapeutic use; D002240:Carbohydrate Sequence; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use; D050111:Imino Sugars / Q000737:chemistry; D016464:Lysosomal Storage Diseases / Q000188:drug therapy; D008969:Molecular Sequence Data
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D050111:Imino Sugars; D006026:Glycoside Hydrolases